In the study of N. Wang et al. (2019) TBF was assessed by PCASL in 52 patients with gliomas of various grades (Grade 1–1 (IDH−), Grade 2–15 (13 IDH+/2 IDH−), Grade 3–13 (9 IDH+/2 IDH−/2 NOS), Grade 4–24 (3 IDH+/21 IDH−). This evidence concerns the gene IDH2 and central nervous system cancer.